Chandra Vargeese Ph.D.
Net Worth

Last updated:

What is Chandra Vargeese Ph.D. net worth?

The estimated net worth of Dr. Chandra Vargeese Ph.D. is at least $6,233,245 as of 22 Jul 2024. He owns shares worth $1,015,060 as insider, has earned $264,585 from insider trading and has received compensation worth at least $4,953,600 in Wave Life Sciences Ltd..

What is the salary of Chandra Vargeese Ph.D.?

Dr. Chandra Vargeese Ph.D. salary is $619,200 per year as Chief Technology Officer in Wave Life Sciences Ltd..

How old is Chandra Vargeese Ph.D.?

Dr. Chandra Vargeese Ph.D. is 64 years old, born in 1961.

What stocks does Chandra Vargeese Ph.D. currently own?

As insider, Dr. Chandra Vargeese Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Wave Life Sciences Ltd. (WVE) Chief Technology Officer 106,624 $9.52 $1,015,060

What does Wave Life Sciences Ltd. do?

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Chandra Vargeese Ph.D. insider trading

Wave Life Sciences Ltd.

Dr. Chandra Vargeese Ph.D. has made 11 insider trades between 2017-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 68,210 units of WVE stock on 22 Jul 2024. As of 22 Jul 2024 he still owns at least 106,624 units of WVE stock.

Transaction Date Security Shares Price per share Total value Source
Option
Share Option (right to buy) 68,210 $2.48 $169,161
Option
Ordinary Shares 68,210 $2.48 $169,161
Sale
Ordinary Shares 10,249 $4.03 $41,303
Sale
Ordinary Shares 16,714 $1.72 $28,748
Sale
Ordinary Shares 10,603 $2.32 $24,599
Sale
Ordinary Shares 3,145 $10.57 $33,243
Sale
Ordinary Shares 3,188 $7.85 $25,026
Option
Ordinary Shares 6,000 $2.48 $14,880
Sale
Ordinary Shares 6,000 $2.48 $14,880
Option
Share Option (right to buy) 6,000 $2.48 $14,880
Sale
Ordinary Shares 2,055 $36.84 $75,706
Sale
Ordinary Shares 3,000 $2.48 $7,440
Option
Ordinary Shares 3,000 $2.48 $7,440
Option
Share Option (right to buy) 3,000 $2.48 $7,440
Option
Share Option (right to buy) 2,000 $2.48 $4,960
Sale
Ordinary Shares 2,000 $2.48 $4,960
Option
Ordinary Shares 2,000 $2.48 $4,960
Sale
Ordinary Shares 2,000 $2.48 $4,960
Option
Share Option (right to buy) 2,000 $2.48 $4,960
Option
Ordinary Shares 2,000 $2.48 $4,960
Option
Share Option (right to buy) 1,500 $2.48 $3,720
Option
Ordinary Shares 1,500 $2.48 $3,720
Sale
Ordinary Shares 1,500 $2.48 $3,720

Wave Life Sciences Ltd. key executives

Wave Life Sciences Ltd. executives and other stock owners filed with the SEC: